Categories: News

Amendment of Disclosures in Past Management Information Circulars

VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) — As a result of a review by the British Columbia Securities Commission, BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic derivative of lysergic acid diethylamide (“LSD”), is issuing the following press release to clarify disclosures in its past Management Information Circulars (“MIC”) as it relates to beneficial ownership by its Chief Executive Officer, Dr. Ahmad Doroudian:

Dates of MIC and
Related Record
Dates

Section in MIC

Amount of Beneficial
Ownership and
Percentage of Class (if
applicable) as
Disclosed in MIC
Amended Amount of
Beneficial Ownership
and Percentage of
Class (if applicable)

February 28 and
February 10, 2023
Proposal No. 2 – Election of
Directors
5,506,367 common 5,863,786 common
November 23 and
November 5, 2021
Proposal No. 2 – Election of
Directors
5,155,162 common 5,529,887 common
November 20 and
November 9, 2020
Voting Securities and
Principal Holders of Voting
Securities
5,155,162 common
13.9%
5,251,637 common
14.2%
February 15 and
February 13, 2019
Principal Stockholders and
Security Ownership of
Management
9,161,929 common
9.455%
21,330,518 common
22.01%

The Company also announces that it has issued 350,000 common shares and 350,000 share purchase warrants pursuant to the conversion of convertible debentures totalling $35,000. Share purchase warrants are exercisable into common shares, on a one-for-one basis, at an exercise price of $0.10 per warrant and expires on August 31, 2026.

About BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non- controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife’s synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent, for composition and method of use, covers treatment of major depressive disorder, anxiety disorder and neuropathic pain and other neuro-psychiatric and neurological disorders.

BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife’s pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.

BetterLife also owns a drug candidate for the treatment of viral infections and is in the process of seeking strategic alternatives for further development.

For further information, please visit BetterLife Pharma.

Contact

David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928

Cautionary Note Regarding Forward-Looking Statements

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

Staff

Recent Posts

Avirmax CMC Successfully Delivers First GMP Lot of AAV Vector Product for Clinical Trial Use

HAYWARD, Calif., July 17, 2024 /PRNewswire/ -- Avirmax CMC, a leader in the innovation and…

2 hours ago

Robbins LLP Reminds ICU Investors with Large Losses to Seek Information About the SeaStar Medical Holding Corporation Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--$ICU #ICU--Robbins LLP reminds investors that a shareholder filed a class action on…

5 hours ago

KORU Medical Systems to Report Second Quarter 2024 Financial Results on August 7, 2024

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical…

8 hours ago

Astrana Health and Elation Health Form Nationwide Partnership to Expand Sustainable Support Infrastructure for Primary Care Physicians

Partnership Will First Launch Value-Based Care Solution Offering to Hawai'i Provider Community ALHAMBRA, Calif., July…

8 hours ago

Waystar to Announce Second Quarter 2024 Financial Results on August 7, 2024

LEHI, Utah and LOUISVILLE, Ky., July 17, 2024 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY),…

8 hours ago